Pars Journal of Medical Sciences

Investigating the prevalence of clarithromycin resistance among Helicobacter pylori strains isolated from patients with digestive problems

Document Type : Original Article

Authors

1 Department of lablatory Sciences, Paramedical Sciences Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Biotechnology Department, Pasteur Institute of Iran, Tehran, Iran

3 Department of Pathology, School of Medicine, Ayatollah Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Proteomics Research Center, Paramedical Sciences Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Introduction: Nowadays occurrence of resistant to clarithromycin which is a key component of eradication therapy
for Helicobacter pylori strains is a worldwide health concern. Point mutations in 23srRNA gene is one of the main causes of clarithromycin resistance. This study aimed to examine rate of clarithromycin resistance and its link with 23srRNA gene point mutation.
Materials and Methods: This study was conducted on 100 patients suffering from gastric complications had referred to Tehran valiasr clinic during january of 2022. Two separate biopsy samples were collected from each patient and used for pathological and microbiological examinations. Antimicrobial susceptibility tests were performed by agar dilution and PCR.
Results: 53% (53/100) of the study patients were diagnosed as H. pylori+. Pathological findings indicated that 54.7% (29/53) of the H.pylori+ patients suffered from Chronic Gastritis, 37.7% (20/53) from Sever Active Gastritis and 7.5% (4/53) with Intestinal Metaplasia. Clarithromycin resistant were found among 13.2% (7/53) of patients. The MIC values of 0.125 mg/L and 2 mg/L were determined as the MIC50 and MIC90 values, respectively. Based on PCR results, all clarithromycin resistant strains had point mutations A2142G in 23SrRNA gene.
Conclusions: The findings revealed the existence of point mutations in 23srRNA gene which may be related with
resistance to clarithromycin in H. pylori strains.

Keywords

1.Guo Y, Cao XS, Guo GY, Zhou MG, Yu B. Effect of Helicobacter Pylori Eradication on Human Gastric Microbiota: A Systematic Review and Meta-Analysis. FRONT CELL INFECT MI. 2022;12:899248.
2. Che H, Xiong Q, Ma J, Chen S, Wu H, Xu H, et al. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. BMC Cancer. 2022;22(1):904.
3. Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. WJCC 2022; 10(19): 6349-6359 [PMID: 35979311 DOI:10.12998/wjcc.v10.i19.6349]
4. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/florence consensus report. Gut. 2017;66(1):6-30. doi:10.1136/gutjnl-2016-312288
5. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. J. Gastroenterol.".. 2017;153(2):420-9.
6. Tran V, Saad T, Tesfaye M, Walelign S, Wordofa M, Abera D, et al. Helicobacter pylori (H. pylori) risk factor analysis and prevalence prediction: a machine learning-based approach. BMC Infect Dis.. 2022;22(1):655.
7. Massarrat S, Saberi-Firoozi M, Soleimani A, et al. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. Eur J Gastroenterol Hepatol. 1995;7:427–33.
8.Goldberg L, Amrick TJ. Successful Eradication of <i>Helicobacter pylori</i> with 5-Day Concomitant Treatment. GastroHep. 2022;2022:1211329.
9. Leung WK, Graham DY. Clarithromycin for Helicobacter pylori infection. Expert Opin Pharmacother. 2000;1(3):507-14.
10. Kocsmár É, Buzás GM, Szirtes I, Kocsmár I, Kramer Z, Szijártó A, et al. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. Nat Commun.. 2021;12(1):2255.
11. Hosseini RS, Rahimian G, Shafigh MH, Validi M, Khaledi M, Gholipour A. Correlation between clarithromycin resistance, virulence factors and clinical characteristics of the disease in Helicobacter pylori infected patients in Shahrekord, Southwest Iran. AMB Express. 2021;11(1):147.
12. Albasha AM, Elnosh MM, Osman EH, Zeinalabdin DM, Fadl AAM, Ali MA, et al. Helicobacter pylori 23S rRNA gene A2142G, A2143G, T2182C, and C2195T mutations associated with clarithromycin resistance detected in Sudanese patients. BMC Microbiology. 2021 2021/02/03;21(1):38.
13.Bordin D, Morozov S, Plavnik R, Bakulina N, Voynovan I, Skibo I, et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017- 2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022:e12924.
14. Gharibi S, Falsafi T, Alebouyeh M, Farzi N, Vaziri F, Zali MR. Relationship between histopathological status of the Helicobacter pylori infected patients and proteases of H. pylori in isolates carrying diverse virulence genotypes. Microbial Pathogenesis. 2017;110:100-6.
15. Kahlmeter G, Brown DF, Goldstein FW, et al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clin Microbiol Infect. 2006;12(6):501-503.
16. Bińkowska A, Biernat MM, Łaczmański Ł, Gościniak G. Molecular Patterns of Resistance Among Helicobacter pylori Strains in South-Western Poland. Front Microbiol. 2018;9:3154. Published 2018 Dec 18.
17. Bohr UR, Primus A, Zagoura A, Glasbrenner B, Wex T, Malfertheiner P. A group-specific PCR assay for the detection of Helicobacteraceae in human gut. Helicobacter. 2002;7(6):378-383.
18. Kauser F, Hussain MA, Ahmed I, et al. Comparative genomics of Helicobacter pylori isolates recovered from ulcer disease patients in England. BMC Microbiol. 2005;5:32.
19. Pan ZJ, Su WW, Tytgat GN, Dankert J, van der Ende A. Assessment of clarithromycin-resistant Helicobacter pylori among patients in Shanghai and Guangzhou, China, by primer-mismatch PCR. J Clin Microbiol. 2002;40(1):259-261.
20. Furuta T, Soya Y, Sugimoto M, et al. Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. J Gastroenterol Hepatol. 2007;22(11):1810-1815.
21. Alexander SM, Retnakumar RJ, Chouhan D, Devi TNB, Dharmaseelan S, Devadas K, et al. Helicobacter pylori in Human Stomach: The Inconsistencies in Clinical Outcomes and the Probable Causes. Front Microbiol. [Review]. 2021 2021-August-17;12.
22. Baghaei K, Shokrzadeh L, Jafari F, Dabiri H, Yamaoka Y, Bolfion M, et al. Determination of Helicobacter pylori virulence by analysis of the cag pathogenicity island isolated from Iranian patients. Dig Liver Dis 2009;41:634-38.
23. Fakheri H, Saberi Firoozi M, Bari Z. Eradication of Helicobacter Pylori in Iran: A Review. Middle East J Dig Dis. 2018;10(1):5-17.
24. Ahmadzadeh A, Ghalehnoei H, Farzi N, et al. Association of CagPAI integrity with severeness of Helicobacter pylori infection in patients with gastritis. Pathol Biol (Paris). 2015;63(6):252-257.
25. Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel). 2020;9(8):436.
26. Yilmaz O, Demiray E. Clinical role and importance of fluorescence in situ hybridization method in diagnosis of Helicobacter pylori infection and determination of clarithromycin resistance in H. pylori eradication therapy. WJG 2007: 13:671-75
27. Khademi F, Poursina F, Hosseini E, Akbari M, Safaei HG. Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. Iran. J. Basic Med.
Sci. 2015;18(1):2-7.
28. Alavifard H, Mirzaei N, Yadegar A, et al. Investigation of Clarithromycin Resistance-Associated Mutations and Virulence Genotypes of Helicobacter pylori Isolated from Iranian PopulationA Cross-Sectional Study. Curr Microbiol.
2021;78(1):244-254.
29. Huang X, Liu Y, Lin Z, et al. Minimum inhibitory concentrations of commonly used antibiotics against Helicobacter Pylori: A multicenter study in South China. PLoS One. 2021;16(9):e0256225.
30. Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europein 2018 and its relationship to antibiotic consumption in the community. Gut 2021;70:1815–1822.
31. De Francesco V, Zullo A, Fiorini G, Saracino IM, Pavoni M, Vaira D. Role of MIC levels of resistance to clarithromycin and metronidazole in Helicobacter pylori eradication. J Antimicrob Chemother. 2018;74(3):772-4.
32. Klesiewicz K., Savari M., Zahedi M.J., Zahedi M.J., Moghadam S.D., Abasi M.H. PCR-RFLP detection of point mutations A2143G and A2142G in 23S rRNA gene conferring resistance to clarithromycin in Helicobacter pylori strains’ Acta Biochim. Pol. 2014;61(2):311–315.
33. Hussein RA, Al-Ouqaili MTS, Majeed YH. Detection of clarithromycin resistance and 23SrRNA point mutations in clinical isolates of Helicobacter pylori isolates: Phenotypic and molecular methods. Saudi J Biol Sci. 2022;29(1):513-520.
34.Farzi N, Yadegar A, Sadeghi A, Asadzadeh Aghdaei H, Marian Smith S, Raymond J, Suzuki H, Zali MR. High Prevalence of Antibiotic Resistance in Iranian Helicobacter pylori Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence Genotyping. J. Clin. Med. 2019; 8(11):2004.
35.Khashei, R.; Dara, M.; Bazargani, A.; Bagheri Lankarani, K.; Taghavi, A.; Moeini, M.; Dehghani, B.; Sohrabi, M. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. APMIS Scand. 2016, 124, 787–793.
36. Seo SI, Do BJ, Kang JG, Kim HS, Jang MK, Kim HY, Shin WG. Helicobacter pylori Eradication According to Sequencing-Based 23S Ribosomal RNA Point Mutation Associated with Clarithromycin Resistance. J. Clin. Med. 2020; 9(1):54.
37. Jaff MS. Relation between ABO blood groups and Helicobacter pylori infection in symptomatic patients. Clin Exp Gastroenterol. 2011;4:221-226. doi:10.2147/CEG.S23019.
38. Ghasemi Basir, Hamid Reza, Mehdi Ghobakhlou, Parvin Akbari, Arash Dehghan, and Mohamad Ali Seif Rabiei. "Correlation between the Intensity of <I>Helicobacter Pylori</I> Colonization and Severity of Gastritis." Gastroenterol Res Pract 2017 (2017/11/28 2017): 8320496.
39. Hojati SA, Kokabpeyk S, Yaghoubi S, Joukar F, Asgharnezhad M, Mansour-Ghanaei F. Helicobacter pylori infection in Iran: demographic, endoscopic and pathological factors. BMC Gastroenterol. 2021;21(1):355.